Enlivex Ltd. ENLV

Company Overview

Enlivex Ltd. is a clinical-stage biopharmaceutical company focused on developing cell-based immunotherapy treatments for life-threatening inflammatory conditions. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on immune modulation rather than pathogen-specific therapies. Enlivex’s core therapeutic approach targets immune system balance, aiming to address conditions characterized by excessive or dysregulated immune responses.

The company’s principal product candidate is Allocetra™, an off-the-shelf cell therapy derived from apoptotic cells designed to rebalance immune responses. Allocetra™ represents Enlivex’s primary revenue driver prospect and strategic focus, as the company does not yet generate commercial product revenue. Enlivex was founded based on academic research originating in Israel and has evolved from early translational research into a publicly traded company listed on NASDAQ under the ticker ENLV, advancing its lead asset through multiple clinical indications.